X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Stock Has Consensus Target Price of $11.25 According to Brokerages

Shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) have been given a consensus rating of “Moderate Buy” by the six brokerages that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have given a buy recommendation to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $11.25.

A number of equities analysts have commented on XFOR shares. Weiss Ratings raised shares of X4 Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, October 2nd. Wells Fargo & Company assumed coverage on shares of X4 Pharmaceuticals in a research note on Friday, July 10th. They set an “overweight” rating and a $11.00 target price for the company.

Insider Activity at X4 Pharmaceuticals

In other news, CFO David Kirske sold 11,767 shares of the business’s stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $2.86, for a total transaction of $33,653.62. Following the completion of the sale, the chief financial officer owned 155,983 shares in the company, valued at $446,111.38. The trade was a 7.01% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Chairman Adam R. Craig sold 47,436 shares of the company’s stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $4.44, for a total value of $210,615.84. Following the completion of the transaction, the chairman directly owned 328,651 shares in the company, valued at $1,459,210.44. The trade was a 12.61% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 83,779 shares of company stock worth $353,387. Insiders own 1.13% of the company’s stock.

Institutional Trading of X4 Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the company. Empery Asset Management LP bought a new stake in X4 Pharmaceuticals in the 4th quarter valued at $35,804,000. Perceptive Advisors LLC grew its holdings in X4 Pharmaceuticals by 6.7% in the 1st quarter. Perceptive Advisors LLC now owns 6,737,648 shares of the company’s stock valued at $27,826,000 after buying an additional 423,196 shares in the last quarter. Bank of New York Mellon Corp bought a new position in X4 Pharmaceuticals during the 2nd quarter worth $917,000. Bank of America Corp DE increased its position in X4 Pharmaceuticals by 321.3% during the 1st quarter. Bank of America Corp DE now owns 150,676 shares of the company’s stock worth $622,000 after buying an additional 114,915 shares during the period. Finally, Squarepoint Ops LLC bought a new position in X4 Pharmaceuticals during the 2nd quarter worth $313,000. 72.03% of the stock is owned by institutional investors and hedge funds.

X4 Pharmaceuticals Price Performance

Shares of XFOR opened at $2.82 on Thursday. The company has a current ratio of 11.30, a quick ratio of 11.02 and a debt-to-equity ratio of 0.49. The company’s fifty day simple moving average is $3.67 and its 200 day simple moving average is $3.93. X4 Pharmaceuticals has a 1-year low of $2.70 and a 1-year high of $4.83. The company has a market cap of $279.60 million, a price-to-earnings ratio of -2.35 and a beta of 0.46.

X4 Pharmaceuticals (NASDAQ:XFOR) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.05. The company had revenue of $8.81 million during the quarter, compared to the consensus estimate of $2.42 million. X4 Pharmaceuticals had a negative net margin of 568.80% and a negative return on equity of 63.05%. On average, research analysts forecast that X4 Pharmaceuticals will post -0.67 earnings per share for the current fiscal year.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases caused by immune and hematologic dysfunction. The company’s research centers on the CXCR4 biological pathway, which regulates the movement and retention of certain immune cells in the bone marrow and other tissues.

X4’s primary product is XOLREMDI (mavorixafor), an oral CXCR4 antagonist approved by the U.S. Food and Drug Administration in 2024 for use in people aged 12 and older with WHIM syndrome.